TriSalus Life Sciences, Inc. filed a Form 8-K with the SEC on September 22, 2026, disclosing that it received U.S. Food and Drug Administration 510(k) clearance for its TriNav Advance device and expects to commence commercialization.
Key Highlights
- FDA 510(k) Clearance: TriSalus Life Sciences received FDA 510(k) clearance for its TriNav Advance device, as announced on September 22, 2026.
- Commercialization Expected: According to the filing, the company expects to commence commercialization following receipt of the clearance.
- Press Release Attached: A press release dated September 22, 2026 was attached as Exhibit 99.1 and incorporated by reference into the report.
- Warrants Also Listed: The company has warrants (TLSIW) listed on the Nasdaq Global Market, each exercisable for one share of common stock at $11.50 per share.
TriSalus Life Sciences Discloses TriNav Advance Device Clearance and Commercialization Plans
TriSalus Life Sciences, Inc. (NASDAQ:TLSI), a Delaware-incorporated company headquartered in Westminster, Colorado, filed a current report disclosing that it received U.S. Food and Drug Administration 510(k) clearance for its TriNav Advance device. The event was reported under Item 8.01 (Other Events) of the Form 8-K, with September 22, 2026 cited as both the date of the report and the date of the earliest event reported.
According to the filing, the company "expects to commence commercialization" following the FDA clearance. The filing did not provide additional details regarding the timeline, commercial terms, or financial projections related to the TriNav Advance device beyond this statement. The full text of the announcement was included in a press release dated September 22, 2026, attached as Exhibit 99.1 and incorporated into the current report by reference.
The filing was signed by David Patience, Chief Financial Officer, on behalf of TriSalus Life Sciences, Inc. The company's common stock, with a par value of $0.0001 per share, is listed on the Nasdaq Global Market under the symbol TLSI. The company's warrants, each exercisable for one share of common stock at an exercise price of $11.50 per share, are also listed on the Nasdaq Global Market under the symbol TLSIW. The filing indicated the company is not classified as an emerging growth company.
What Was Disclosed
TriSalus Life Sciences reported receipt of FDA 510(k) clearance for its TriNav Advance device on September 22, 2026, and stated it expects to commence commercialization. A supporting press release was filed as Exhibit 99.1.




Please wait processing your request...